Header Logo

Connection

KENNETH MCCLAIN to Histiocytosis, Langerhans-Cell

Back to Details
This is a "connection" page, showing publications KENNETH MCCLAIN has written about Histiocytosis, Langerhans-Cell.
KENNETH MCCLAIN
Connection Strength
13.394
Histiocytosis, Langerhans-Cell
  1. Treatment of Langerhans cell histiocytosis with subcutaneous cytarabine. Pediatr Hematol Oncol. 2023; 40(5):497-505.
    View in: PubMed
    Score: 0.610
  2. BRAF V600E vs cell of origin: what governs LCH? Blood. 2021 10 07; 138(14):1203-1204.
    View in: PubMed
    Score: 0.559
  3. Histiocytic disorders. Nat Rev Dis Primers. 2021 10 07; 7(1):73.
    View in: PubMed
    Score: 0.559
  4. Histiocytic Diseases of Neonates: Langerhans Cell Histiocytosis, Rosai-Dorfman Disease, and Juvenile Xanthogranuloma. Clin Perinatol. 2021 03; 48(1):167-179.
    View in: PubMed
    Score: 0.531
  5. Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):395-399.
    View in: PubMed
    Score: 0.527
  6. Rituximab therapy for patients with Langerhans cell histiocytosis-associated neurologic dysfunction. Pediatr Hematol Oncol. 2018 Oct - Nov; 35(7-8):427-433.
    View in: PubMed
    Score: 0.461
  7. Anti TNF-a therapy in patients with relapsed and refractory Langerhans cell histiocytosis: a phase II study. Pediatr Hematol Oncol. 2018 Aug - Sep; 35(5-6):362-368.
    View in: PubMed
    Score: 0.458
  8. Langerhans-Cell Histiocytosis. N Engl J Med. 2018 08 30; 379(9):856-868.
    View in: PubMed
    Score: 0.451
  9. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018 06 15; 124(12):2607-2620.
    View in: PubMed
    Score: 0.438
  10. Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood. 2016 11 17; 128(20):2462-2465.
    View in: PubMed
    Score: 0.395
  11. How I treat Langerhans cell histiocytosis. Blood. 2015 Jul 02; 126(1):26-35.
    View in: PubMed
    Score: 0.356
  12. Treatment of Langerhans cell histiocytosis: it is time to learn from the past: response to Minkov and Rodriguez-Galindo. Br J Haematol. 2015 Oct; 171(1):150-1.
    View in: PubMed
    Score: 0.356
  13. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis. 2013 May 14; 8:72.
    View in: PubMed
    Score: 0.312
  14. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One. 2012; 7(8):e43257.
    View in: PubMed
    Score: 0.297
  15. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol. 2010 Apr 15; 184(8):4557-67.
    View in: PubMed
    Score: 0.250
  16. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr Blood Cancer. 2010 Mar; 54(3):416-23.
    View in: PubMed
    Score: 0.250
  17. Interleukin-17A is not expressed by CD207(+) cells in Langerhans cell histiocytosis lesions. Nat Med. 2009 May; 15(5):483-4; author reply 484-5.
    View in: PubMed
    Score: 0.236
  18. Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition. Blood. 2019 04 11; 133(15):1691-1694.
    View in: PubMed
    Score: 0.232
  19. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009 Jan; 52(1):97-101.
    View in: PubMed
    Score: 0.231
  20. EBV+ lymphoproliferative disease following prolonged chemotherapy for refractory LCH. Pediatr Blood Cancer. 2008 Mar; 50(3):728-30.
    View in: PubMed
    Score: 0.218
  21. Langerhans cell histiocytosis: a review of past, current and future therapies. Drugs Today (Barc). 2007 Sep; 43(9):627-43.
    View in: PubMed
    Score: 0.210
  22. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007 Jan; 48(1):44-9.
    View in: PubMed
    Score: 0.201
  23. Clofarabine for relapsed/refractory LCH and non-LC histiocytosis. Blood Adv. 2026 07 28; 10(14):5087-5096.
    View in: PubMed
    Score: 0.195
  24. Current Approaches Among Medical Providers Treating Pediatric Langerhans Cell Histiocytosis. Pediatr Blood Cancer. 2026 Sep; 73(9):e70525.
    View in: PubMed
    Score: 0.195
  25. Disease extent, not lesion location, determines relapse risk in single-system skeletal Langerhans cell histiocytosis. Blood Adv. 2026 07 14; 10(13):4776-4785.
    View in: PubMed
    Score: 0.194
  26. Drug therapy for the treatment of Langerhans cell histiocytosis. Expert Opin Pharmacother. 2005 Nov; 6(14):2435-41.
    View in: PubMed
    Score: 0.185
  27. BRAF V600E-positive mononuclear cells in blood at diagnosis portend treatment failure and neurodegeneration in pediatric LCH. Blood. 2025 07 10; 146(2):206-218.
    View in: PubMed
    Score: 0.181
  28. Approach to the Patient: From Endocrinopathy to the Diagnosis of a Histiocytic Disorder. J Clin Endocrinol Metab. 2025 May 19; 110(6):1756-1766.
    View in: PubMed
    Score: 0.179
  29. Mixed histiocytic disorders: Nature versus nurture? Br J Haematol. 2024 Jul; 205(1):20-21.
    View in: PubMed
    Score: 0.167
  30. Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures. Cancer. 2024 Jul 15; 130(14):2416-2439.
    View in: PubMed
    Score: 0.167
  31. Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1888-1893.
    View in: PubMed
    Score: 0.166
  32. Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1882-1887.
    View in: PubMed
    Score: 0.166
  33. Atypical cellular disorders. Hematology Am Soc Hematol Educ Program. 2004; 283-96.
    View in: PubMed
    Score: 0.163
  34. Circulating senescent myeloid cells infiltrate the brain and cause neurodegeneration in histiocytic disorders. Immunity. 2023 12 12; 56(12):2790-2802.e6.
    View in: PubMed
    Score: 0.162
  35. Langerhans cell histiocytosis patients have HLA Cw7 and DR4 types associated with specific clinical presentations and no increased frequency in polymorphisms of the tumor necrosis factor alpha promoter. Med Pediatr Oncol. 2003 Dec; 41(6):502-7.
    View in: PubMed
    Score: 0.162
  36. Need for a cooperative study: Pulmonary Langerhans cell histiocytosis and its management in adults. Med Pediatr Oncol. 2002 Jul; 39(1):35-9.
    View in: PubMed
    Score: 0.147
  37. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022 04 28; 139(17):2601-2621.
    View in: PubMed
    Score: 0.145
  38. BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nat Med. 2021 05; 27(5):851-861.
    View in: PubMed
    Score: 0.136
  39. Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. Blood. 2021 04 01; 137(13):1777-1791.
    View in: PubMed
    Score: 0.135
  40. Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells. Blood Adv. 2020 01 14; 4(1):87-99.
    View in: PubMed
    Score: 0.124
  41. BRAF-V600E-mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor. Blood Adv. 2019 06 25; 3(12):1848-1853.
    View in: PubMed
    Score: 0.119
  42. The role of parental and perinatal characteristics on Langerhans cell histiocytosis: characterizing increased risk among Hispanics. Ann Epidemiol. 2018 08; 28(8):521-528.
    View in: PubMed
    Score: 0.110
  43. RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med. 2018 01 02; 215(1):319-336.
    View in: PubMed
    Score: 0.107
  44. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. Pediatr Blood Cancer. 2018 Jan; 65(1).
    View in: PubMed
    Score: 0.106
  45. A genome-wide association study of LCH identifies a variant in SMAD6 associated with susceptibility. Blood. 2017 11 16; 130(20):2229-2232.
    View in: PubMed
    Score: 0.106
  46. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood. 2017 07 13; 130(2):167-175.
    View in: PubMed
    Score: 0.103
  47. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis. Hematol Oncol. 2018 Feb; 36(1):307-315.
    View in: PubMed
    Score: 0.101
  48. A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2017 05; 64(5).
    View in: PubMed
    Score: 0.099
  49. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood. 2016 11 24; 128(21):2533-2537.
    View in: PubMed
    Score: 0.099
  50. Cell(s) of Origin of Langerhans Cell Histiocytosis. Hematol Oncol Clin North Am. 2015 Oct; 29(5):825-38.
    View in: PubMed
    Score: 0.091
  51. Recognition and treatment of concurrent active and neurodegenerative langerhans cell histiocytosis: a case report. J Pediatr Hematol Oncol. 2015 Jan; 37(1):e37-40.
    View in: PubMed
    Score: 0.087
  52. Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood. Br J Haematol. 2015 Apr; 169(2):241-8.
    View in: PubMed
    Score: 0.087
  53. Up-front therapy for LCH: is it time to test an alternative to vinblastine/prednisone? Br J Haematol. 2015 Apr; 169(2):299-301.
    View in: PubMed
    Score: 0.087
  54. Differentiating skin-limited and multisystem Langerhans cell histiocytosis. J Pediatr. 2014 Nov; 165(5):990-6.
    View in: PubMed
    Score: 0.086
  55. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014 Nov 06; 124(19):3007-15.
    View in: PubMed
    Score: 0.086
  56. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014 Apr 07; 211(4):669-83.
    View in: PubMed
    Score: 0.083
  57. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer. 2014 Mar; 61(3):479-87.
    View in: PubMed
    Score: 0.080
  58. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013 Jun 20; 121(25):5006-14.
    View in: PubMed
    Score: 0.078
  59. Neither IL-17A mRNA nor IL-17A protein are detectable in Langerhans cell histiocytosis lesions. Mol Ther. 2011 Aug; 19(8):1433-9.
    View in: PubMed
    Score: 0.068
  60. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010 Jun; 156(6):873-881.e1.
    View in: PubMed
    Score: 0.064
  61. Diabetes insipidus in Langerhans cell histiocytosis: When is treatment indicated? Pediatr Blood Cancer. 2009 May; 52(5):555-6.
    View in: PubMed
    Score: 0.059
  62. Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry. J Pediatr. 2008 Nov; 153(5):700-5, 705.e1-2.
    View in: PubMed
    Score: 0.056
  63. In vivo transformation of mouse conventional CD8alpha+ dendritic cells leads to progressive multisystem histiocytosis. Blood. 2008 Feb 15; 111(4):2073-82.
    View in: PubMed
    Score: 0.053
  64. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2005 Mar; 44(3):251-4.
    View in: PubMed
    Score: 0.044
  65. Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis. J Immunol. 2005 Mar 01; 174(5):3067-71.
    View in: PubMed
    Score: 0.044
  66. Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004 Jul; 43(1):81-4.
    View in: PubMed
    Score: 0.042
  67. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer. 2004 May; 42(5):438-44.
    View in: PubMed
    Score: 0.042
  68. Adult Langerhans cell histiocytosis limited to the skin. Dermatology. 2003; 207(2):157-61.
    View in: PubMed
    Score: 0.038
  69. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020 05 28; 135(22):1929-1945.
    View in: PubMed
    Score: 0.032
  70. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 2010 Jan; 16(1 Suppl):S82-9.
    View in: PubMed
    Score: 0.015
  71. Acquired immune deficiency, myelodysplasia, and acute nonlymphocytic leukemia associated with monosomy 7 and t(3;3) (q21;q26) in a child with Langerhans cell histiocytosis. Am J Pediatr Hematol Oncol. 1989; 11(2):153-7.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.